RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 8 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. All subjects are required to provide archived tissue (5 unstained sections) obtained within the previous 2 years or fresh tissue for ROR1 expression testing at the central laboratory; in addition, relapsed/refractory lymphoma subjects are required to provide tissue sections used for previous pathological diagnosis for pathological consultation at the central laboratory;

    Inclusion criterion 8

  3. Dose escalation phase: Histopathologically confirmed relapsed/refractory B-cell lymphoma following at least 2 prior lines of systemic therapy;

    Inclusion criterion 6

    Relapsed/refractory B-cell lymphoma: Subjects in Phase Ia dose escalation phase should have evaluable lesions; subjects in Phase Ib dose expansion phase should have at least 1 radiographically measurable lymph node or extranodal malignant tumor lesion (intranodal lesion defined as having a long diameter > 1.5 cm; extranodal lesion having a long diameter > 1.0 cm) as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) according to 2014 Lugano criteria, and a lesion that has previously received radiotherapy is considered measurable when it shows unequivocal progression after completion of radiotherapy;

    Inclusion criterion 9

    Subjects must have recovered (to ≤ Grade 1) from any AE associated with prior anticancer therapy;

    Inclusion criterion 11

    Subjects with prior allogeneic HSCT who have developed acute graft-versus-host disease (GVHD) or persistent evidence of chronic GVHD (as manifested by ≥ Grade 2 serum bilirubin, ≥ Grade 3 skin involvement, or ≥ Grade 3 diarrhea or receiving systemic immunosuppressive therapy/prophylaxis for GVHD);

    Exclusion criterion 3

  4. B-cell lymphoma: ECOG performance status of 0-2;

    Inclusion criterion 3

    Advanced solid tumors: ECOG performance status of 0-1;

    Inclusion criterion 4

  5. Advanced solid tumors: subjects are required to have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 ;

    Inclusion criterion 10

  6. Active infectious disease, such as HIV infection, active hepatitis B, active hepatitis C (positive RNA result), active syphilis;

    Exclusion criterion 13

  7. Female subjects of childbearing potential should agree to use contraception methods (e.g., intrauterine device, contraceptive pill, or condom) during the study and for 6 months after the end of the study; have a negative serum pregnancy test within 7 days before study enrollment; and male subjects should agree to use contraceptive avoidance measures during the study and for 6 months after the end of the study.

    Inclusion criterion 13

    Female subjects who are pregnant, lactating or planning to become pregnant during the study;

    Exclusion criterion 17

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06615193, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Agree to follow the study treatment protocol and visit schedule, enroll voluntarily and sign a written informed consent;
  • Male or female aged ≥ 18 years at the time of signing the ICF;
  • B-cell lymphoma: ECOG performance status of 0-2;
  • Advanced solid tumors: ECOG performance status of 0-1;
  • Life expectancy of at least 3 months;
  • Dose escalation phase: Histopathologically confirmed relapsed/refractory B-cell lymphoma following at least 2 prior lines of systemic therapy;
  • Dose expansion phase: relapsed/refractory B-cell lymphoma and advanced or metastatic solid tumor of specified type.
  • All subjects are required to provide archived tissue (5 unstained sections) obtained within the previous 2 years or fresh tissue for ROR1 expression testing at the central laboratory; in addition, relapsed/refractory lymphoma subjects are required to provide tissue sections used for previous pathological diagnosis for pathological consultation at the central laboratory;
  • Relapsed/refractory B-cell lymphoma: Subjects in Phase Ia dose escalation phase should have evaluable lesions; subjects in Phase Ib dose expansion phase should have at least 1 radiographically measurable lymph node or extranodal malignant tumor lesion (intranodal lesion defined as having a long diameter > 1.5 cm; extranodal lesion having a long diameter > 1.0 cm) as assessed by computed tomography (CT)/magnetic resonance imaging (MRI) according to 2014 Lugano criteria, and a lesion that has previously received radiotherapy is considered measurable when it shows unequivocal progression after completion of radiotherapy;
  • Advanced solid tumors: subjects are required to have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 ;
  • Subjects must have recovered (to ≤ Grade 1) from any AE associated with prior anticancer therapy;
  • Subjects have adequate organ and bone marrow function;
  • Female subjects of childbearing potential should agree to use contraception methods (e.g., intrauterine device, contraceptive pill, or condom) during the study and for 6 months after the end of the study; have a negative serum pregnancy test within 7 days before study enrollment; and male subjects should agree to use contraceptive avoidance measures during the study and for 6 months after the end of the study.

Exclusion Criteria:

  • B-cell lymphoma: known central nervous system (CNS) involvement .
  • Advanced solid tumors: Patients with active brain metastases (defined as stable for < 4 weeks, or symptomatic, or requiring antiepileptic drug/hormonal therapy, or meningeal metastases);
  • Subjects with prior allogeneic HSCT who have developed acute graft-versus-host disease (GVHD) or persistent evidence of chronic GVHD (as manifested by ≥ Grade 2 serum bilirubin, ≥ Grade 3 skin involvement, or ≥ Grade 3 diarrhea or receiving systemic immunosuppressive therapy/prophylaxis for GVHD);
  • Subjects have another primary malignancy ,with the following exceptions: adequately treated non-melanoma skin cancer without evidence of disease recurrence and adequately treated carcinoma in situ without evidence of disease recurrence,et al;
  • History of severe bleeding disorders ;
  • History of chronic pancreatitis or acute pancreatitis within 6 months;
  • History of interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease;
  • Patients with uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage after intubation and drainage, VEGF inhibitors, platinum and other drugs injection (subjects with stable symptoms for at least one week after treatment can be enrolled);
  • Prior solid organ transplantation;
  • Persistent peripheral neuropathy > Grade 1 at baseline;
  • Clinically significant cardiovascular or cerebrovascular diseases;
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic therapy (except for localized skin or nail bed fungal infection) at enrollment;
  • Active infectious disease, such as HIV infection, active hepatitis B, active hepatitis C (positive RNA result), active syphilis;
  • Receiving corticosteroids (prednisone equivalent more than 30 mg/day);
  • Contraindication to any component of HDM2005;
  • History of drug anaphylactic shock, severe food allergy, uncontrolled asthma/COPD;
  • Female subjects who are pregnant, lactating or planning to become pregnant during the study;
  • Known history of mental illness or substance abuse that would impair the subject's ability to cooperate with study requirements;
  • Prior or current evidence of any disease, treatment, or laboratory abnormality that, in the opinion of the investigator, could affect the outcome of the study, prevent the subject from participating in the study entirely, or is not in the subjects' best interest.

Quoted from ClinicalTrials.gov, NCT06615193, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06615193, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06615193